The future outlook of 3D bioprinting is significant particularly in biomedicine for the creation of personalized medicine, drug screening, tissue replacement and future organ transplant. In the area of green technology, bioprinted algae have potential applications in bioremediation and providing sustainable environmental solutions in various industries. In addition, there are other non-traditional applications that would greatly benefit from the precision and automation tools provided in bioprinting technology. These applications have the potential to impact an incredible range of consumer and medical products.


Dr Mayasari Lim is the founder and CEO of SE3D, a startup focused on next generation lab automation in 3D bioprinting and assays for laboratories and education. Prior to starting her own venture, she was an Assistant Professor in the School of Chemical and Biomedical Engineering at Nanyang Technological University (NTU) in Singapore. Her research expertise included stem cell engineering, bioprocess design, bioprinting and tissue engineering. Apart from her strong belief in the potential of bioprinting technology, she is greatly passionate about training next generation minds for our future. Dr. Lim obtained her Ph.D. degree in Chemical Engineering at Imperial College London and her B.Sc. in Chemical Engineering at UC Berkeley.